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Background: Anti-angiogenic therapy inhibits tumor growth and is considered as a potential clinical therapy
for malignant glioma. However, inevitable recurrences and unexpected tumor resistance, particularly increased
invasion ability of glioma cell, were observed after anti-angiogenic treatment. The underlying mechanism remains
undetermined. Focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) are closely associated with cell
migration; therefore, we investigated the possible role of these kinases in rat C6 glioma cell invasion induced by
bevacizumab, a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF).
Methods: The effects of bevacizumab on migration and invasion of C6 glioma cells were investigated in vitro
and in vivo. The cells proliferation, migration, and invasion were determined by MTT assay, wound healing, and
transwell assay, respectively. Invasive potential of glioma cells in vivo was assessed by counting vimentin-positive
cells crossing the solid tumor rim by immunohistochemical staining. The total and phosphorylated protein levels of
FAK and Pyk2 were detected by Western blotting.
Results: Bevacizumab exposure increased migration and invasion of cultured C6 cells in a concentration-dependent
manner. In addition, the continuous bevacizumab treatment also promoted tumor invasion in rat C6 intracranial
glioma models. Bevacizumab treatment enhanced Pyk2 phosphorylation at Tyr402, but no effect on FAK
phosphorylation at Tyr397 both in vitro and in vivo. Knockdown of Pyk2 by siRNA or inhibition of Pyk2
phosphorylation by Src kinase specific inhibitor PP1 partially inhibited bevacizumab-induced cell invasion in
cultured C6 glioma cells. Furthermore, the combined administration of bevacizumab and PP1 significantly
suppressed glioma cell invasion into surrounding brain tissues compared to bevacizumab treatment alone in
experimental rats.
Conclusions: These results suggest that anti-VEGF treatment promotes glioma cell invasion via activation of Pyk2.
Inhibition of Pyk2 phosphorylation might be a potential target to ameliorate the therapeutic efficiency of anti-VEGF
treatment.
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Glioma is the most common primary malignant tumor of
the central nervous system (CNS) with poor prognosis.
Many vessel-related pathological signs were observed in
glioma and aberrant microvasculature usually appears as
“glomeruloid tufts” consisting of multilayered, mitotically
active endothelial cells and perivascular cells [1,2]. With
the increasing accumulation of knowledge regarding
angiogenesis, anti-angiogenic therapy has also been devel-
oped and considered as an optimistic strategy for glioma
patients [3,4]. Bevacizumab, a recombinant monoclonal
antibody targeted against VEGF-A, has been received a
conditional approval for the treatment of recurrent
high-grade gliomas. In addition, clinical trials have also
been performed in patients with newly diagnosed glio-
blastoma multiforme (GBM). Improved progression-
free survival and maintenance of baseline quality of life
and performance status were observed in GBM patients
received combined treatment of bevacizumab and
radiotherapy–temozolomide [5-10]. The anti-angiogenic
property of bevacizumab is generally considered as a
critical contributor to its anti-tumor activity. With the
angiogenesis-targeted therapy widely accepted, inevit-
able recurrence and unexpected tumor resistance, espe-
cially increased ability of glioma cell invasion were also
observed after anti-VEGF treatment [11-16]. Because
the disruption of VEGF autocrine loop after anti-VEGF
therapy, it was also thought to be important for the gli-
oma cell phenotypic change [13,14]. Unexpected tumor
resistance to bevacizumab aroused the additional inves-
tigation on direct effects of anti-VEGF therapy on
tumor cell migration and invasion. However, the exact
mechanism underlying tumor resistance to bevacizu-
mab remains to be elucidated.
Glioma invasion is a complicated process including
cell interactions with extracellular matrix (ECM) and ad-
jacent cells, and cell migration. Many factors are in-
volved in this process, such as cadherins, intracellular
adhesion molecules, matrix metalloproteinase, myosin II,
and so on [17]. It is well known that cell-matrix and
cell-cell junction cross-talk together, and these two junc-
tions cooperatively regulate cell adhesion, polarization,
and movement [18]. Integrins are one of the classic cell
adhesion molecules that mediate cell attachment to
ECM [17], which is a critical process in tumor invasion.
The binding of integrins to ECM leads to the recruit-
ment of focal adhesion kinase (FAK) and/or proline-rich
tyrosine kinase (Pyk2) to the newly formed focal adhe-
sion sites. Activation of FAK and Pyk2 is followed by
phosphorylation of a variety of downstream effectors,
resulting in cell migration, proliferation, and angiogen-
esis [19,20]. Previous studies have also demonstrated
that the expression of FAK and Pyk2 was significantly
correlated with the malignant grade of astrocytic tumors[21], and that down-regulation of FAK expression inhib-
ited glioma cell proliferation and induced apoptosis [22].
Our previous study also showed an association of FAK
and Pyk2 protein level with VEGF expression and angio-
genesis in human glioma [23]. Recently, it was reported
that hypoxia contributed to up-regulation of β1 integrin
and its downstream effector FAK during bevacizumab
therapy, thus promoting mechanisms of survival and
evasion [24]. However, little is known about the role of
FAK and Pyk2 in glioma cell invasion after anti-VEGF
treatment.
The aim of this study was to determine whether FAK
and/or Pyk2 are involved in glioma cell invasion induced
by anti-VEGF therapy. We investigated protein levels
and their activation of FAK and Pyk2 in glioma cells
after anti-VEGF treatment, and then analyzed the correl-
ation of these proteins with glioma cell invasion both
in vitro and in vivo. Our results showed that the phos-
phorylation of Pyk2, but not of FAK, was increased after
anti-VEGF treatment. In addition, increased Pyk2 phos-
phorylation was involved in the promotion of glioma cell
invasion after anti-VEGF treatment. The present study
underlines the need to combine anti-angiogenic treat-
ment in glioma with drugs capable of specifically target-
ing Pyk2 to direct more effective therapy.Methods
Cell culture
The rat C6 glioma cell line was obtained from the Chinese
Type Culture Collection (Chinese Academy of Sciences,
Shanghai, China). C6 glioma cells were cultured in DMEM
supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 U/ml penicillin G and 100 μg/ml strepto-
mycin sulfate (Invitrogen, USA) at 37°C in an atmosphere
of 95% air and 5% CO2. Bevacizumab or control IgG treat-
ment was performed as previously described [13]. Pyk2-
specific siRNA (Santa Cruz Biotechnology, USA) were
used to knockdown Pyk2 expression. Src family kinases in-
hibitor 4-amino-5-(4-methylphenyl)-7-(t-butyl) pyrazolo
[3,4-d]-pyrimidine (PP1, Santa Cruz Biotechnology, USA)
was used to inhibit Pyk2 phosphorylation [19].Cell proliferation assay
C6 cells were seeded into 96-well plates at a density of
5 × 104 cells/well in 100 μl culture medium and allowed
to grow for 24 hours. After 12 hours of incubation in
serum-free medium to induce cell differentiation, cells
were then treated with control IgG or bevacizumab for
72 hours [13]. Cell proliferation was detected by MTT
assay [22]. Experiments were repeated at least three
times with triplicate wells and the data were expressed
as the relative MTT reduction against control.
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The cell migration assay was done using the wound-
healing method [25]. Briefly, C6 cells were seeded into
6-well plates with density of 5 × 105 cells/well and grown
to 90% confluence. An artificial homogenous wound was
made onto the monolayer with a sterile plastic 200 μL
micropipette tip. After wounding, cell debris was re-
moved by washing the cells with warm serum-free
medium. After incubation for another 24 hours, the cells
that had migrated into the wounded area or with ex-
tended protrusion from the border of the wound were
photographed using an inverted microscope (40 ×mag-
nifications, Olympus, Japan).
In vitro cell invasion assay
The in vitro invasive ability of glioma cells was assessed
using the modified Boyden chamber method [25]. In brief,
glioma cells pretreated with control IgG or bevacizumab
for 72 hours were added in triplicate to the diluted
matrigel-precoated Transwells (Corning Corp. USA) with
density of 1 × 105 cells per well. Serum-free medium was
added to the lower chambers of the plate. The indicated
concentration of bevacizumab alone or bevacizumab plus
Pyk2 siRNA or inhibitor PP1 was added to both the upper
and bottom chambers. After 24 hours of incubation at
37°C, non-invading cells on the upper surface of the mem-
brane were scrubbed gently with a cotton-tipped swab.
The invasive cells on the lower surface of the membrane
were fixed with 95% methanol and stained with 0.1% crys-
tal violet (Sigma-Aldrich, MO, USA). Stained invasive cells
were photographed under an inverted light microscope
and quantified by manual counting in three randomly se-
lected areas of view.
Western blotting analysis
Western blotting [25] was performed to detected protein
expression and its phosphorylation statues by using spe-
cific antibodies against β-actin (1:2000), FAK (1:2000),
phosphorylated FAK (Tyr397, 1:1000), Pyk2 (1:1000) or
phosphorylated Pyk2 (Tyr402, 1:1000). All of these anti-
bodies were purchased from Santa Cruz Biotechnology
(USA). The protein bands were quantitatively analyzed
by Kodak Digital Science ID software (Eastman Kodak
Company, USA). Uneven sample loading was normalized
using the intensity ratio of the immunoreactive bands of
the tested proteins relative to the expression of β-actin.
Rat intracranial glioma xenografts
The animal research was approved by the Institutional
Committee of Animal Care and Use of Zhongnan Hos-
pital, Wuhan University, China. C6 glioma cells (5 × 105)
were stereotactically implanted into the brain (posterior
to the bregma and 3 mm to the right of the midline su-
ture at a depth of 2.5 mm) of experimental rats. Threeweeks later after the implantation, animals were treated
with bevacizumab (weekly, 10 mg/kg) or control IgG by
tail vein injection. Additional intraperitoneal administra-
tion of PP1 (three times per week, 1mg/kg) was per-
formed to investigate the role of Pyk2 phosphorylation
in bevacizumab treatment-induced tumor invasion. All
of these separate or combined treatments were applied
to implanted rats for 3 weeks in accordance with current
clinical practice [26]. Rats were sacrificed and whole
brain tissue was dissected for preparing immunohisto-
chemical staining and total tumor tissues for western
blotting.
Evaluation of glioma xenograft invasiveness
Paraffin embedded brain tissue sections (4 μm thick)
from xenografts were used for immunohistochemical
analysis. Standard biotin–streptavidin immunohisto-
chemical staining was performed according to the man-
ufacturer’s instructions (Boster, China) as previously
described [3]. Invasive potential of glioma was assessed
by counting vimentin-positive cells crossing the solid
tumor rim [27]. A blinded observer determined tumor
cell invasion by quantifying the number of invading cells
on sections selectively stained with anti-vimentin anti-
body (Santa Cruz Biotechnology, CA, USA). The num-
ber of individual cells crossing the solid tumor rim was
counted in multiple fields of equivalent size and tumor
position.
Statistical analysis
All values were presented as the mean ± S.E.M. Statis-
tical analysis including Student’s t-test analysis for 2
groups or one-way ANOVA for multiple groups’ com-
parisons. Differences were considered statistically signifi-
cant at p < 0.05.
Results
Bevacizumab treatment promoted migration and invasion
of glioma cell
To exclude the possible contribution of an imbalance in
cell proliferation and viability to cell migration and inva-
sion after anti-VEGF treatment, cell proliferation and via-
bility under different concentrations (0, 2.5, 5 and 10 mg/
ml) of bevacizumab were measured by MTT assay before
invasion experiment. Control IgG and bevacizumab-
treated cells exhibited similar levels of viability after hours,
with the exception of treatment with 10 mg/ml bevacizu-
mab (Figure 1). Therefore, a dose of bevacizumab less
than 10 mg/ml was used in cultured cells.
Next, we investigated the effect of anti-VEGF treatment
on the ability of C6 glioma cells to migrate and invade
in vitro. Increased migration and invasion of treated C6
cells were observed by wound healing and transwell assay
in a concentration-dependent manner. Compared with
Figure 1 Effect of bevacizumab (Bev) on glioma cell
proliferation. After treatment with the indicated concentrations of
Bev for 72 hours, cell proliferation rates were analyzed by MTT assay.
The growth rates of cells with the IgG control were defined as 1.0
(*p < 0.05 vs the group treated with IgG control).
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and invasive cells (Figure 2B-C) were much higher when
the cells were exposed to 5 mg/mL of bevacizumab. To
further explore whether the bevacizumab treatment in-
duces a similar promotion pattern of cell migration andFigure 2 Effect of bevacizumab (Bev) on glioma cell migration and in
with 5 mg/ml Bev was evaluated by wound healing assay. The representat
100 ×magnification. (B) C6 glioma cell invasion was evaluated by transwel
cells were photographed under an inverted light microscope at 100 ×mag
The experiments were performed in triplicate with three independent expeinvasion in vivo, a rat C6 intracranial xenograft model was
employed. The administration of 10 mg/kg bevacizumab
for 3 weeks resulted in a significant increase in invasive
tumor cells outside the tumor rim, visualized by vimentin
staining (Figure 3), suggesting that anti-VEGF treatment
induced an increased ability of cell migration and invasion
both in cultured C6 cells and in intracranial C6 glioma cell
xenograft.
Bevacizumab treatment activated Pyk2 but had no effect
on FAK activity
Due to the important role of FAK and Pyk2 in the for-
mation of focal adhesions, a key process in cell migra-
tion and invasion, changes in total protein level of FAK
and Pyk2 after anti-VEGF treatment were examined. As
shown in Figure 4, the similar total protein level of FAK
and Pyk2 was observed in cultured C6 cells exposed to
IgG and bevacizumab (Figure 4A, 4B and 4D). The ac-
tivity of FAK and Pyk2 is regulated by phosphorylation
at Tyr397 and Tyr402, respectively [28]. Therefore, we
further investigated the phosphorylation state of FAK at
Tyr397 and Pyk2 at Tyr402 in culture C6 cells treated
with IgG or bevacizumab. Interestingly, different phos-
phoryaltion patterns of FAK and Pyk2 were induced
after bevacizumab treatment. Compared to IgG, bevaci-
zumab exposure induced an increase in Pyk2 phosphor-
ylation (Figure 4A and 4C), but showed no influence onvasion in vitro. (A) The migratory ability of C6 glioma cells treated
ive images at 0 hour and 24 hours post-wounding are shown at
l assay after 5 mg/ml Bev treatment for 24 hours. The stained invasive
nification. (C) Quantitative results of C6 glioma cell invasion in vitro.
riments.
Figure 3 Effect of bevacizumab (Bev) on glioma cell migration and invasion in vivo. (A) Rat C6 glioma xenografts treated with or without
Bev were stained immunohistochemically for vimentin to show invasion of the tumor cells. Tumor cells were shown to have invaded the
surrounding normal brain after Bev treatment, while the leading edge of the control tumor showed a clear rim. Scale bar: 100 μm. (B)
Quantification of vimentin-positive cells outside the tumor rim with or without Bev treatment. The number of individual cells crossing the solid
tumor rim was counted in five fields of view. The invasive tumor cell number of the group without Bev treatment was expressed as 100%
(*p < 0.05, **p < 0.01, vs. the group treated with IgG control).
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changes of the FAK and Pyk2 phosphorylation were also
observed in intracranial tumor tissue of rats treated with
bevacizumab (Figure 5). These results suggested that
bevacizumab treatment increased phosphorylation of
Pyk2 but not FAK both in vitro and in vivo.
Inhibition of Pyk2 decreased bevacizumab-induced
glioma cell invasion in vitro
Because only elevated Pyk2 phosphorylation was observed
after bevacizumab treatment, we then explored whether
Pyk2 was involved in increased C6 glioma cells migration
and invasion induced by bevacizumab treatment. For thisFigure 4 Effect of bevacizumab (Bev) on phosphorylation of FAK and
phosphorylation of FAK at Tyr397 and Pyk2 at Tyr402 in C6 glioma cells. (B
in (A). (D, E) Quantification of total protein levels and phosphorylation of Fpurpose, we used Pyk2-specific small interfering RNA to
knockdown Pyk2 expression, or the Src kinase inhibitor
PP1 to inhibit Pyk2 phosphorylation [19]. In order to ex-
clude the effect of reduced cell proliferation by Src kinase
inhibitor on glioma cell invasion, different PP1 concen-
trations were tested and 10 μM of PP1 was employed to
perform following experiments at which PP1 did not
display anti-proliferation effect (see Additional file 1).
The efficiency of Pyk2 siRNA or PP1 was confirmed by
immunoblotting analysis (Figure 6A and 6C). Further-
more, combined treatment of bevacizumab with Pyk2
siRNA or PP1 significantly inhibited C6 glioma cells in-
vasion when compared to bevacizumab treatment alonePyk2 in cultured glioma cells. (A) Protein expression and
, C) Quantification of total protein levels and phosphorylation of Pyk2
AK in (A). (**p < 0.01, vs. IgG control).
Figure 5 Effect of bevacizumab (Bev) on phosphorylation of FAK and Pyk2 in rat intracranial glioma model. (A) Protein expression and
phosphorylated FAK at Tyr397 and Pyk2 at Tyr402 in intracranial glioma tissue of rats treated with Bev or IgG control. (B, C) Quantification of total
protein levels and phosphorylation of Pyk2 in (A). (D, E) Quantification of total protein levels and its phosphorylation of FAK in (A). (**p < 0.01, vs.
IgG control).
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(Figure 6B and 6D), suggesting the involvement of Pyk2
phosphorylation in bevacizumab-induced C6 giloma cell
invasion.
Combination of PP1 decreased bevacizumab-induced
invasion in rat intracranial glioma
To verify the promotion effect of Pyk2 on glioma cell in-
vasion after anti-VEGF treatment in vivo, tumor cellFigure 6 Effect of Pyk2 inhibition on glioma cell invasion in cultured
Pyk2 siRNA or control siRNA (**p < 0.01, vs. control siRNA group). (B) Quant
group). (C) Phosphorylated Pyk2 in C6 glioma cells treated with PP1 (*p < 0
glioma cells after treatment with Bev, Bev plus DMSO, and Bev plus PP1 (*pinvasiveness surrounding the tumor rim in rat C6 intra-
cranial xenograft was evaluated by vimentin staining [27]
after bevacizumab treatment with or without Pyk2 inhib-
ition. Compared with bevacizumab treatment alone, a sig-
nificant decrease in the number of tumor cells invading
normal brain tissues was observed after treatment with
bevacizumab plus PP1 (Figure 7). Bevacizumab treatment
was also found to prolong the survival of rat with intracra-
nial xenograft. Although combination of bevacizumab andglioma cells. (A) Total Pyk2 protein in C6 glioma cells treated with
ification of the number of invasive glioma cells (*p < 0.05, vs. Bev
.05, vs. control group). (D) Quantification of the number of invasive
< 0.05, vs. Bev group).
Figure 7 Effect of Pyk2 inhibition by PP1 on tumor cell invasiveness after bevacizumab (Bev) treatment in vivo. (A) Rat C6 glioma
xenografts treated with Bev alone or Bev plus PP1 were stained immunohistochemically for vimentin to show the invasion of tumor cells. In the
Bev alone treated group, tumor cells had clearly invaded the surrounding normal brain. However, the necrotic areas (N) in the Bev plus PP1
treated tumors increased and the tumor cells invading the surrounding normal brain decreased. The right upper corner shows a higher
magnification image (boxed inset). (B) Quantification of vimentin-positive cells invading the surrounding normal brain with Bev alone or Bev plus
PP1 treatment. The number of individual cells crossing the solid tumor rim was counted in five fields. The invasive tumor cell number of the
group treated with Bev alone were expressed as 100% (**p < 0.01, vs. the group treated with Bev alone).
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in the median survival duration of rat with intracranial
xenograft between bevacizumab group and bevacizumab
plus PP1 group (Figure 8).
Discussion
Tumor cell invasion into the normal extracellular matrix
is a key feature of malignant gliomas. It was considered
as a limiting factor in the treatment, and as a critical fac-
tor in the clinical course of glioma because of its role in
tumor recurrence. As angiogenesis-dependent invasion
exists in glioma [17], anti-angiogenic therapy might the-
oretically decrease tumor cell invasion, yet clinical obser-
vations are not always consistent with this expectation.
Some patients for whom anti-angiogenic treatment fails
had an uncharacteristic pattern of tumor progression
and an apparent phenotypic shift to a predominantlyFigure 8 Effect of bevacizumab treatment alone or
combination with PP1 on survival of rat C6 glioma xenografts.
Kaplan-Meier survival curves for control IgG versus treated rats. Bev
and Bev plus PP1 treatments resulted in a longer median survival
duration compared with control, but no difference was found
between Bev group and Bev plus PP1 group.infiltrative pattern of tumor progression after bevacizu-
mab treatment was observed [14]. Similarly, other recent
studies showed that treatment with anti-VEGFR specific
monoclonal antibody caused a striking increase in tumor
cell invasion and metastasis [16,29,30]. In accord with
these studies, we also observed the increased cell migra-
tion and invasion in bevacizumab-treated C6 cells, both
in vitro and in vivo. These studies provide evidence sup-
porting the notion that glioma cells can directly be af-
fected by anti-VEGF or anti-VEGFR treatment and
disruption of VEGF-VEGFR autocrine loop in tumor
cells maybe result in glioma cell phenotypic change.
These findings will help to explain the resistance to anti-
angiogenic therapies observed in clinic, and raise the
question of how to elicit tumor cell invasion with anti-
angiogenic therapies.
The difference between experiment-driven hypothesis
and actual clinical practice indicates that glioma pro-
gression is governed by complex mechanisms, which are
still not clearly understood. Invasion of tumor cells into
normal tissue is thought to be a multifactorial process,
consisting of cellular interactions with ECM and adja-
cent cells, and accompanying biochemical processes sup-
portive of active cell movement. Glioma cell invasion
requires four distinct processes including detachment of
invading cells from the primary tumor mass, adhesion to
the ECM, degradation of the ECM by proteases, and cell
motility and intracellular contractility [17,31]. During
these processes, focal adhesion formation regulated by
FAK and Pyk2 is a key step for cell invasion.
Many malignant human tumors exhibit increased FAK
expression and tyrosine phosphorylation, which are both
correlated with the acquisition of an invasive cellular
phenotype and increased tumor metastasis [32]. Al-
though Pyk2 shares a number of functionally important
residues with FAK, Pyk2 has a more limited tissue ex-
pression than FAK. Particularly, Pyk2 is highly enriched
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much more frequently and with higher expression scores
within the different world health organization (WHO)
grades of astrocytic tumors, although significant co-
expression of FAK and Pyk2 in astrocytomas has been
demonstrated [21]. Whether these two tyrosine kinases
are involved in glioma cell invasion that was induced by
bevacizumab therapy remains unclear. In present study,
we first investigated the changes in total and active FAK
and Pyk2 protein levels after bevacizumab treatment.
Compared with IgG control treatment, the phosphoryl-
ation level of Pyk2 at Tyr402 significantly increased after
bevacizumab treatment, although the total levels of Pyk2
protein were similar. This suggested that the invasion
potential of C6 glioma cells induced by bevacizumab
might be correlated with the level of activated Pyk2, but
not as a consequence of increased levels of the total
amount of Pyk2 protein. Furthermore, inhibition of Pyk2
phosphorylation partially reversed the invasive ability of
glioma cells that was induced by bevacizumab treatment
both in vivo and in vitro. These results indicated that ac-
tivation of Pyk2 might be involved in the promotion of
glioma cell invasion by anti-VEGF treatment.
Interestingly, neither the total amount of FAK protein
nor the phosphorylated FAK at Tyr397 changed after
bevacizumab treatment, suggesting that anti-VEGF ther-
apy might have different effects on the activation of FAK
and Pyk2. It also implicated that FAK and Pyk2 might
play differential roles in regulating the biological behav-
ior of glioma cells. Lipinski et al. [34] investigated the
role of FAK and Pyk2 in the phenotypic determination
of four different human glioblastoma cell-lines (U118,
G112, SF767 and T98G). Their results showed that in-
creased FAK activity correlated with high proliferation
and low migratory rates, while Pyk2 activity was signifi-
cantly increased in migratory cell-lines (SF767 or T98G)
and was dampened in the proliferative cell-lines (U118
or G112). Overexpression of Pyk2 stimulated migration,
whereas FAK overexpression inhibited cell migration and
instead stimulated cellular proliferation. In contrast, other
studies showed that FAK expression was associated with
melanoma metastases [35] and FAK phosphorylation reg-
ulated U-87 glioma cell migration and invasion [28]. These
data suggests that both FAK and Pyk2 function as import-
ant signaling effectors in glioma, but their differential
regulation might be a deterministic factor in the temporal
development of proliferative or migrational phenotypes. In
our study, the discrepant changes in FAK and Pyk2 activity
after bevacizumab treatment also provided evidence that
favored differential roles for FAK and Pyk2 on glioma cell
migration and proliferation. Recently, a potential novel
role for FAK as a nonlinear, dose-dependent regulator of
angiogenesis was demonstrated and stromal-FAK hetero-
zygosity was showed to be sufficient to enhance tumorgrowth and tumor angiogenesis. FAK-heterozygous
endothelial cells displayed an imbalance in FAK phos-
phorylation at Tyr397 and Tyr861 without changes in
the activity of Pyk2 or Erk1/2. Cell proliferation and
microvessel sprouting, but not migration, were increased
in serum-stimulated FAK-heterozygous endothelial cells
[36]. It’s implicated that FAK and/or Pyk2 may possess dif-
ferent biological function in different cell types including
tumor cell and intratumor endothelial cell. Taken together,
despite significant sequence homology and biological simi-
larity between FAK and Pyk2, these varying outcomes
with regard to the role of FAK in tumor cell migration
and invasion suggest that more research is required to bet-
ter understand the function of FAK and Pyk2.
Although inhibition of Pyk2 decreased glioma cell in-
vasion, there was no difference in the median survival
duration of rat with intracranial xenograft between beva-
cizumab treatment group and bevacizumab plus PP1
treatment group, suggesting that the development of gli-
oma is a complex process. It should be difficult to block
tumor progress by single inhibitors against only one set
of proteins. Indeed, our knowledge about the therapeutic
action of bevacizumab and its resistance is constantly
being updated. Regression of GBM after bevacizumab
treatment, also known as “magic radiological disappear-
ance” effect of bevacizumab, is now verified to be associ-
ated with its modification of vascular permeability to
gadolinium. Therefore, previous radiological criteria to
evaluate the response of GBM to bevacizumab have been
modified [37,38]. According to these new evalution cri-
teria, recent data revealed that recurrence pattern after
bevacizumab treatment in naive-GBM patients was not
different between groups of other therapy. However, it is
critical that many patients progress after an initial re-
sponse to this drug [10]. Mechanisms of tumor resistant
and recurrence are appealing and different hypothesis
are noted. Our and other findings support the notion
that anti-VEGF treatment can directly promote glioma
cell invasive ability by regulating the activity of some
molecules [13,14]. The other widely realized mechanism
is that hypoxic microenvironment caused by anti-VEGF
treatment leads to the changes of related gene expres-
sion and then enhances tumor cell invasion [24,26]. All
these findings suggest that the invasive process in vivo is
highly complicated. Therefore, the role of VEGF recep-
tors and the hypoxic microenvironment should be inves-
tigated in further studies about the effect of FAK and/or
Pyk2 on glioma cell invasion after anti-VEGF treatment.
In addition, a limitation of the current study is that we
did not observe the effect of combining bevacizumab
with temozolomide and/or radiotherapy, which is used
as clinical therapeutic protocol. So, relative studies should
be performed in future in order to reflect a true clinical
practice.
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To our knowledge, this is the first study to focus on the
role of FAK and Pyk2 in the promotion of glioma cell in-
vasion induced by anti-VEGF treatment. In summary,
anti-VEGF treatment enhanced phosphorylation of Pyk2,
but not FAK, leading to the promotion of glioma cell in-
vasion. Our study underlines the need to combine anti-
angiogenic treatment with drugs targeting Pyk2 in gli-
oma. More importantly, a better understanding of the
molecular components responsible for glioma angiogen-
esis and tissue invasion will hopefully lead to the devel-
opment of new and improved treatment approaches.
Additional file
Additional file 1: Effect of different PP1 concentrations on C6
glioma cell proliferation. The effects of different PP1 concentrations
from 10 μM to 50 μM on C6 glioma cell proliferation were tested. 10 μM
of PP1 did not display anti-proliferation effect. More than 10 μM of PP1
exhibited anti-proliferative effect (*p < 0.05, vs. control group).
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